An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1 - PubMed (original) (raw)
An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1
Simon Brackenridge et al. J Virol. 2011 Jun.
Abstract
Mutations within MHC class I-restricted epitopes have been studied in relation to T cell-mediated immune escape, but their impact on NK cells via interaction with killer Ig-like receptors (KIRs) during early HIV infection is poorly understood. In two patients acutely infected with HIV-1, we observed the appearance of a mutation within the B*57-restricted TW10 epitope (G9E) that did not facilitate strong escape from T cell recognition. The NK cell receptor KIR3DL1, carried by these patients, is known to recognize HLA-B*5703 and is associated with good control of HIV-1. Therefore, we tested whether the G9E mutation influenced the binding of HLA-B*5703 to soluble KIR3DL1 protein by surface plasmon resonance, and while the wild-type sequence and a second (T3N) variant were recognized, the G9E variant abrogated KIR3DL1 binding. We extended the study to determine the peptide sensitivity of KIR3DL1 interaction with epitopes carrying mutations near the C termini of TW10 and a second HLA-B*57-restricted epitope, IW9. Several amino acid changes interfered with KIR3DL1 binding, the most extreme of which included the G9E mutation commonly selected by HLA-B*57. Our results imply that during HIV-1 infection, some early-emerging variants could affect KIR-HLA interaction, with possible implications for immune recognition.
Figures
Fig. 1.
Viral evolution and CD8+ T cell recognition of the TW10 G9E variant in patient CH58. (A) Sequence analysis of the TW10 epitope in single genome amplified (SGA) viral RNA for patient CH58, illustrating the gradual decline of the wildtype (WT) TW10 epitope, coincident with the emergence of the G9E and T3N variants. Times are given in days from enrollment (E). G9E was detected as the dominant virus between days 45 and 85, and gradually declined thereafter. The T3N variant subsequently emerged as the dominant variant and was prevalent from day 154 onwards (data are from reference 11). (B) Interfeon-γ ELISPOT assays were used compare recognition of the founder viral TW10 epitope (TSTLQEQIGW) with that of the G9E and T3N variants in donor CH58. PBMCs were incubated overnight in the presence of varying amounts of each peptide (10−11 to 10−5 M). Responses are reported as spot-forming cells (SFC) per million PBMCs.
Fig. 2.
Generation of specific HLA-B*5703 tetramers by UV-ligand exchange. Biotinylated, UV-sensitive HLA-B*5703-9MT4 complexes were photoilluminated and rescued in the presence of HLA-B*5703-restricted KAFSPEVIPMF (KF11), TSTLQEQIGW (TW10), HTQGYFPDW (HW9), and QASQEVKGW (QW9) epitopes prior to tetramer generation via conjugation to an extravidin-phycoerythrin (PE)-labeled fluorochrome. (A) The functionality and specificity of UV-exchanged B*5703-KF11 tetramers was confirmed by staining a B*5703-KF11-restricted CD8+ T cell clone with conventional KF11 tetramer and KF11, TW10, and QW9 tetramers produced by UV exchange. Comparable staining was observed using both KF11 tetramers (open boxes), while the irrelevant UV exchange tetramers failed to bind KF11-specifc T cells. (B) The specificities of B*5703-TW10 and HW9 tetramers were evaluated by staining HW9- and TW10-specific CD8+ T cell lines (day 12) derived from a single donor in vitro.
Fig. 3.
Integrity and specificity of soluble KIR3DL1-Fc. (A) The integrity of KIR3DL1-Fc was assessed by antibody binding, using the KIR3DL1-specific antibodies Z27 (which binds a linear epitope) and DX9 (conformation dependent). After the level of saturation binding of each antibody was corrected for the amount of KIR3DL1 protein immobilized in the SPR flow cell, the proportion of DX9-reactive material (correctly folded) to Z27-reactive material (total protein) was calculated as 61%. (B) The specificity of KIR3DL1 was assessed by comparing its binding to immobilized HLA-B*5703 (Bw4 motif) and B*8101 (Bw6 motif) complexes. (C) The preferential binding of KIR3DL1 to Bw4 serotypes does not reflect differences in the amounts of protein immobilized in the SPR flow cell. The data were corrected for the amount of MHC class I protein immobilized in each flow cell and are shown as both normalized binding (with the level of binding to HLA-B5703 set at 1) and fold change in binding of HLA-B*8101 compared with HLA-B*5703.
Fig. 4.
Loss of KIR3DL1 binding to the G9E TW10 variant. (A) Biotinylated B*5703-β2m complexes, irradiated and rescued in the presence of peptides corresponding to the wild-type TW10 epitope and the G9E (red) and T3N (cyan) variants, were immobilized on SA sensor chips, over which a fixed concentration of soluble KIR3DL1-Fc was injected at a constant flow rate. (B) Loss of binding of KIR3DL1 to HLA-B*5703 containing the G9E peptide did not reflect differences in the amount of material immobilized on the surface of the SPR flow cell. The data were corrected for the amount of MHC class I protein immobilized in each flow cell and are shown as both normalized binding (with the level of binding to the wild-type peptide set at 1) and fold change in binding of the G9E and T3N variants compared with the wild type.
Fig. 5.
Ligand-specific binding of KIR3DL1 to HLA-B*5703 in complex with C−1 and C−2 TW10 and IW9 variants. The sensitivity of KIR3DL1 binding in the presence of peptide epitope variants incorporating amino acid substitutions is illustrated for the entire panel of TW10 and IW9 C−1 positional variants (A and B) and a subset of C−2 TW10 and IW9 variants (C and D). The data sets were normalized relative to the total amount of MHC class I protein immobilized in the SPR flow cells and are shown as fold change in binding relative to the wild-type amino acid (G for TW10 C−1, I for TW10 C−2, A for IW9 C−1, and N for IW9 C−2) and are ranked in ascending order for the TW10 variants. The IW9 data sets are ranked in the same order as the corresponding TW10 data set. The coloring of the graphs reflects the physical properties of the individual amino acids (see Table S1 in the supplemental material).
Similar articles
- Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules.
Fadda L, O'Connor GM, Kumar S, Piechocka-Trocha A, Gardiner CM, Carrington M, McVicar DW, Altfeld M. Fadda L, et al. J Virol. 2011 Jun;85(12):5970-4. doi: 10.1128/JVI.00412-11. Epub 2011 Apr 6. J Virol. 2011. PMID: 21471246 Free PMC article. - MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape.
Pymm P, Illing PT, Ramarathinam SH, O'Connor GM, Hughes VA, Hitchen C, Price DA, Ho BK, McVicar DW, Brooks AG, Purcell AW, Rossjohn J, Vivian JP. Pymm P, et al. Nat Struct Mol Biol. 2017 Apr;24(4):387-394. doi: 10.1038/nsmb.3381. Epub 2017 Feb 20. Nat Struct Mol Biol. 2017. PMID: 28218747 Free PMC article. - Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa.
Hölzemer A, Thobakgale CF, Jimenez Cruz CA, Garcia-Beltran WF, Carlson JM, van Teijlingen NH, Mann JK, Jaggernath M, Kang SG, Körner C, Chung AW, Schafer JL, Evans DT, Alter G, Walker BD, Goulder PJ, Carrington M, Hartmann P, Pertel T, Zhou R, Ndung'u T, Altfeld M. Hölzemer A, et al. PLoS Med. 2015 Nov 17;12(11):e1001900; discussion e1001900. doi: 10.1371/journal.pmed.1001900. eCollection 2015 Nov. PLoS Med. 2015. PMID: 26575988 Free PMC article. - The role genes encoding of killer cell immunoglobulin-like receptors (KIRs) and their ligands in susceptibility to and progression of HIV infection.
Błachowicz O, Zwolińska K. Błachowicz O, et al. Postepy Hig Med Dosw (Online). 2016 Dec 31;70(0):1409-1423. doi: 10.5604/17322693.1227771. Postepy Hig Med Dosw (Online). 2016. PMID: 28100849 Review. - KIR-HLA intercourse in HIV disease.
Carrington M, Martin MP, van Bergen J. Carrington M, et al. Trends Microbiol. 2008 Dec;16(12):620-7. doi: 10.1016/j.tim.2008.09.002. Epub 2008 Oct 29. Trends Microbiol. 2008. PMID: 18976921 Free PMC article. Review.
Cited by
- Identification of a Clade-Specific HLA-C*03:02 CTL Epitope GY9 Derived from the HIV-1 p17 Matrix Protein.
Kyobe S, Mwesigwa S, Nkurunungi G, Retshabile G, Egesa M, Katagirya E, Amujal M, Mlotshwa BC, Williams L, Sendagire H, On Behalf Of The CAfGEN Consortium, Kiragga D, Mardon G, Matshaba M, Hanchard NA, Kyosiimire-Lugemwa J, Robinson D. Kyobe S, et al. Int J Mol Sci. 2024 Sep 6;25(17):9683. doi: 10.3390/ijms25179683. Int J Mol Sci. 2024. PMID: 39273630 Free PMC article. - The structure of songbird MHC class I reveals antigen binding that is flexible at the N-terminus and static at the C-terminus.
Eltschkner S, Mellinger S, Buus S, Nielsen M, Paulsson KM, Lindkvist-Petersson K, Westerdahl H. Eltschkner S, et al. Front Immunol. 2023 Jul 7;14:1209059. doi: 10.3389/fimmu.2023.1209059. eCollection 2023. Front Immunol. 2023. PMID: 37483599 Free PMC article. - Epitope length variants balance protective immune responses and viral escape in HIV-1 infection.
Pymm P, Tenzer S, Wee E, Weimershaus M, Burgevin A, Kollnberger S, Gerstoft J, Josephs TM, Ladell K, McLaren JE, Appay V, Price DA, Fugger L, Bell JI, Schild H, van Endert P, Harkiolaki M, Iversen AKN. Pymm P, et al. Cell Rep. 2022 Mar 1;38(9):110449. doi: 10.1016/j.celrep.2022.110449. Cell Rep. 2022. PMID: 35235807 Free PMC article. - A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies.
McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, Zale E, Stevenson EM, Patel S, Brumme CJ, Dong W, Jones DS, Andresen TL, Walker BD, Brumme ZL, Bollard CM, Perelson AS, Irvine DJ, Jones RB. McCann CD, et al. J Exp Med. 2021 Jul 5;218(7):e20201908. doi: 10.1084/jem.20201908. Epub 2021 May 14. J Exp Med. 2021. PMID: 33988715 Free PMC article. - High-throughput identification of conditional MHCI ligands and scaled-up production of conditional MHCI complexes.
Darwish M, Wichner S, Li J, Chang JC, Tam C, Franke Y, Li H, Chan P, Blanchette C. Darwish M, et al. Protein Sci. 2021 Jun;30(6):1169-1183. doi: 10.1002/pro.4082. Epub 2021 Apr 26. Protein Sci. 2021. PMID: 33840137 Free PMC article.
References
- Alter G., et al. 2007. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J. Infect. Dis. 195:1452–1460 - PubMed
- Anfossi N., et al. 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331–342 - PubMed
- Anfossi N., et al. 2004. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J. Immunol. 173:7223–7229 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 081894/Wellcome Trust/United Kingdom
- G0501011/MRC_/Medical Research Council/United Kingdom
- MC_U137884177/MRC_/Medical Research Council/United Kingdom
- A1067854/PHS HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials